Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial

Complete the form below to unlock access to ALL audio articles.
"The timely completion of patient recruitment and the two month patient follow up sets the stage for reporting top line SHIGATEC results early in the second quarter," said Dr. Allan Mandelzys, Thallion's Chief Executive Officer. "With the achievement of this significant milestone, we are now focused on moving forward with our anticipated Phase III clinical trial."
"We remain excited about the potential Shigamabs® represents in delivering an important therapy to the thousands of people who suffer from this terrible and potentially life-threatening infection each year" said Guillaume Bologna, Executive Vice-President for Development Programs of LFB Biotechnologies.